These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 9667245

  • 1. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia.
    Cheson BD, Frame JN, Vena D, Quashu N, Sorensen JM.
    J Clin Oncol; 1998 Jul; 16(7):2313-20. PubMed ID: 9667245
    [Abstract] [Full Text] [Related]

  • 2. Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature.
    Hussain K, Mazza JJ, Clouse LH.
    Am J Hematol; 2003 Mar; 72(3):212-5. PubMed ID: 12605395
    [Abstract] [Full Text] [Related]

  • 3. Acute tumour lysis syndrome after oral fludarabine in a patient with chronic lymphocytic leukaemia.
    Ramachandran A, Majumdar G.
    Hematol J; 2004 Mar; 5(6):528-9. PubMed ID: 15570297
    [Abstract] [Full Text] [Related]

  • 4. Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
    Calvo-Villas JM, Urcuyo BM, Umpierrez AM, Sicilia F.
    Onkologie; 2008 Apr; 31(4):197-9. PubMed ID: 18418022
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine.
    Montalban C, Liaño F, Aguilera A.
    Postgrad Med J; 1994 Sep; 70(827):651-2. PubMed ID: 7971632
    [Abstract] [Full Text] [Related]

  • 7. Fludarabine and acute tumor lysis in chronic lymphocytic leukemia.
    Frame JN, Dahut WL, Crowley S.
    N Engl J Med; 1992 Nov 05; 327(19):1396-7. PubMed ID: 1406856
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.
    J Clin Oncol; 2007 Mar 20; 25(9):1114-20. PubMed ID: 17296974
    [Abstract] [Full Text] [Related]

  • 11. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F.
    Haematologica; 2000 Dec 20; 85(12):1268-70. PubMed ID: 11114133
    [Abstract] [Full Text] [Related]

  • 12. Acute tumor lysis syndrome during oral fludarabine treatment for CLL--a rare event that might be observed more frequently in the future.
    Rioufol C, Coiffier B.
    Onkologie; 2008 Apr 20; 31(4):157-8. PubMed ID: 18418014
    [No Abstract] [Full Text] [Related]

  • 13. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
    Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR.
    Leuk Res; 2015 May 20; 39(5):495-500. PubMed ID: 25804339
    [Abstract] [Full Text] [Related]

  • 14. Fludarabine causing tumour lysis syndrome in chronic lymphocytic leukaemia.
    Mulligan SP, Dean MG.
    Aust N Z J Med; 1994 Aug 20; 24(4):406-7. PubMed ID: 7980241
    [No Abstract] [Full Text] [Related]

  • 15. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
    Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA.
    N Engl J Med; 2000 Dec 14; 343(24):1750-7. PubMed ID: 11114313
    [Abstract] [Full Text] [Related]

  • 16. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
    Rogers KA, Lu X, Emond B, Côté-Sergent A, Kinkead F, Lafeuille MH, Lefebvre P, Huang Q.
    J Manag Care Spec Pharm; 2022 Sep 14; 28(9):1033-1045. PubMed ID: 35816124
    [Abstract] [Full Text] [Related]

  • 17. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.
    Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC.
    J Clin Oncol; 1998 May 14; 16(5):1885-9. PubMed ID: 9586905
    [Abstract] [Full Text] [Related]

  • 18. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
    Martell RE, Peterson BL, Cohen HJ, Petros WP, Rai KR, Morrison VA, Elias L, Shepherd L, Hines J, Larson RA, Schiffer CA, Hurwitz HI.
    Cancer Chemother Pharmacol; 2002 Jul 14; 50(1):37-45. PubMed ID: 12111110
    [Abstract] [Full Text] [Related]

  • 19. Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
    Cheson BD, Heitner Enschede S, Cerri E, Desai M, Potluri J, Lamanna N, Tam C.
    Oncologist; 2017 Nov 14; 22(11):1283-1291. PubMed ID: 28851760
    [Abstract] [Full Text] [Related]

  • 20. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
    Perkins JG, Flynn JM, Howard RS, Byrd JC.
    Cancer; 2002 Apr 01; 94(7):2033-9. PubMed ID: 11932906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.